---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-039225"
form_type: "8-K"
ticker: "ABSI"
cik: "0001672688"
company_name: "Absci Corp"
filed_at: "2024-09-04T23:59:59+00:00"
generated_at: "2026-05-31T06:27:18.023876+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Absci completes first milestone in AstraZeneca oncology collaboration; AI-designed antibodies delivered

## Summary
- Absci delivered AI-designed antibody sequences to AstraZeneca, fulfilling first milestone under December 2023 collaboration.
- AstraZeneca elected to advance sequences into AI-lead optimization phase.
- Collaboration combines Absci's Integrated Drug Creation platform with AstraZeneca's oncology expertise.
- Goal: accelerate discovery of a potential new cancer treatment candidate.

## SEC filing metadata
- accession: 0001628280-24-039225
- form_type: 8-K
- ticker: ABSI
- cik: 0001672688
- company_name: Absci Corp
- filed_at: 2024-09-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672688/000162828024039225/0001628280-24-039225-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672688/000162828024039225/absc-20240904.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-039225
- JSON: https://secwatch.observer/filing/0001628280-24-039225.json
- Plain text: https://secwatch.observer/filing/0001628280-24-039225.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.